Merck announces positive data from phase 3 trials that show the investigational, once─daily, oral, two─drug regimen of ...
Merck, known as MSD outside of the United States and Canada, announced the presentation of positive results from two pivotal phase 3 trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0. …